Downregulation of hnRNP K by RNAi inhibits growth of human lung carcinoma cells

FENGMING TANG1,2, WEIMIN LI1, YAN CHEN1, DONGMEI WANG1, JUAN HAN1 and DAN LIU1

1Department of Respiratory Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan 610041; 2Department of Respiratory Medicine, The First People's Hospital of Yibin, Yibin, Sichuan 644000, P.R. China

Received July 10, 2013; Accepted December 12, 2013

DOI: 10.3892/ol.2014.1832

Abstract. Lung cancer is one of the most common malignancies worldwide, but its pathogenesis remains unknown. The current study examined the effects of heterogeneous nuclear ribonucleoprotein K (hnRNP K)-targeted small interfering RNA (siRNA) on the growth and apoptosis of lung cancer cells in vitro. The expression of hnRNP K was studied by the SP method of immunohistochemistry in lung tissue samples of 70 cases of lung cancer. hnRNP K siRNA were transfected into human lung cancer cell line, A549, using Lipofectamine 2000. Cells transfected with siRNA and untreated served as controls. The inhibitory effect of siRNA on the expression of hnRNP K mRNA and protein was detected by reverse transcription polymerase chain reaction and western blot analysis. The change in cell cycling and cell apoptosis of siRNA-treated cells was detected by flow cytometry. The rates of positive hnRNP K expression in lung tumors of diameters ≤3, 3-5 and ≥5 cm, were 38.5, 95.2 and 91.7%, respectively. A significant difference was identified between lung tumors with diameters of ≤3 and ≥3 cm (P<0.01). The expression of hnRNP K mRNA was significantly inhibited in siRNA-transfected cells compared with that in control cells (P<0.05). Notably, hnRNP K protein decreased in hnRNP K siRNA-transfected cells, but exhibited no effect on the control groups. siRNA targeting human hnRNP K effectively inhibited the growth of lung cancer cell line, A549, and the distribution of the cell cycle. The apoptosis rate was 4.79% and the number of cells increased in the G0/G1 phase from 37.21 to 85.60% and decreased in the S and G2/M phases from 47.71 to 13.50% and 14.00 to 0.32%, respectively, following 24 h of transfection. hnRNP K siRNA promotes A549 apoptosis and the apoptosis rate was 4.79% (P<0.01). Therefore, hnRNP K siRNA may inhibit the proliferation of A549 cells. In addition, hnRNP K promotes the growth of lung cancer cells and, therefore, hnRNP K siRNA may inhibit the growth and increase the apoptosis of lung cancer cells.

Introduction

Heterogeneous nuclear RNAs (hnRNAs), from which mRNAs are generated by RNA processing, associate with specific nuclear proteins to form large hnRNP complexes (1,2). These hnRNPs bind pre-mRNAs and are considered to be important in mRNA biogenesis (3,4), nucleocytoplasmic transport of mRNA (5-7) and cytoplasmic mRNA trafficking (8). To date, 21 hnRNPs (A through U) have been identified. Certain hnRNPs are emerging as having an important involvement in tumor development (9).

Heterogeneous ribonucleoprotein K (hnRNP K) is a 464-amino acid protein with three K homology domains that mediate DNA and RNA binding and contain nuclear localization and nuclear shuttling domains (10,11). Based on these domains, we presumed that the hnRNP K protein is involved in multiple steps of gene expression, including transcription, RNA splicing and translation; such presumptions were later confirmed. In addition, a hnRNP protein potentially relevant in tumorigenesis is hnRNP K. In the nucleus, this protein binds directly to the promoter region of the human c-myc gene and functions as a transcription factor (12). When localized to the cytoplasm, hnRNP K inhibits the translation of specific mRNAs, such as 15-lipoxygenase mRNA (13). In breast cancer cells, hnRNP K significantly enhances cell proliferation and anchorage-independent growth through a growth factor dependent mechanism (14). The present study investigated the effects of hnRNP K siRNA on the growth of lung cancer cells in vitro.

Materials and methods

Study sample. A total of 70 cases of lung cancer were identified by pathology at the Department of Thoracic Surgery, West China Hospital of Sichuan University (Chengdu, China) between 2004 and 2005, in which there were 53 males and 17 females. The average age was 58.12 years and ranged between 46.2 and 70.04 years. The tumors from surgical resection included 13 samples with diameters of ≤3 cm, 20 samples with diameters between 3 and 5 cm and 56 samples with diameters of ≥5 cm. A549 lung cancer cell strains were obtained

Key words: heterogeneous nuclear ribonucleoprotein K, siRNA, A549

Correspondence to: Professor Weimin Li, Department of Respiratory Medicine, West China Hospital of Sichuan University, 37 Guo Xue Lane, Chengdu, Sichuan 610041, P.R. China
E-mail: weimi003@yahoo.com
from the West China Hospital Respiratory Lab (Chengdu, China). Institutional review board approval for the present study was obtained from the Ethics Committee of Sichuan University (Chengdu, China) and written informed consent was obtained from all patients.

**Materials.** Dulbecco’s modified Eagle’s medium, Lipofectamine™ 2000, TRIZol reagent and RPMI-1640 were purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). The T7 RiboMAX™ Express RNAi system kit and Access reverse transcription (RT)-polymerase chain reaction (PCR) introductory system were purchased from Promega Corporation (Madison, W1, USA). Monoclonal antibodies against hnRNP K were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).

**Immunohistochemistry.** Tumor tissues were fixed with paraformaldehyde (4%), paraffin-embedded and sectioned onto Plus slides (Thermo Electron Corp., Madison, WI, USA). Following antigen retrieval, endogenous peroxidase activity was inhibited (with 3% H2O2 in 50% methanol) and sections were blocked. Sections were then incubated with primary antibody. Following washing with phosphate-buffered saline (PBS), the sections were incubated with goat anti-mouse antibody conjugated to biotin. Then, following avidin-biotin-horseradish peroxidase amplification (Vectorstain ABC Reagent; Vector Laboratories, Inc., Burlingame, CA, USA), the sections were incubated with filtered 3,3'-diaminobenzidine until the desired stain intensity had developed. Following subsequent washing with PBS, the slides were counterstained with hematoxylin. According to the Matthew classified criteria and combining the chromogenic strength and proportion of positive cells, the results were classified into three degrees between - and ++.

**Preparation of siRNA.** The sequence data of human hnRNP K mRNA (BC025321; gi: 19116261) used were collected from GenBank (Bethesda, MD, USA). siRNA targeting human hnRNP K and one nonsense siRNA were designed online and obtained by transcription using a kit purchased from the Shanghai Shen Gong Chemical Co., Ltd. (Shanghai, China). The following sequences of hnRNP K siRNA were used: Sense: 5'-gatccccCTATTCCCAAGATTTGGCttcaagaga-3', anti-sense: 5'-agcttttccaaaaCTATTCCAAAGATTTGGCctctcttgaaGCCAAATCTTTGGGAATAGtttttggaaa-3'. The predominant cDNA amplification product was 141 bp in length. (1.5×10⁵/l) were suspended in RPMI-1640, plated onto six-well culture plates and incubated in a humidified incubator containing 5% CO₂ for 24 h at 37°C. Following transfection with siRNAs for 24 h, cells were collected and total RNA was extracted.

In total, 35 cycles of PCR were performed at 94°C for 3 min, 53°C for 30 sec, 72°C for 60 sec and a final extension at 72°C for 5 min. Following electrophoresis and ethidium bromide staining, DNA bands were visualized using an ultraviolet transilluminator (Ultra-Violet Products Ltd., Cambridge, UK). The results were scanned onto a computer to measure DNA band intensities.

**Western blot analysis.** Cytoplasmic and nuclear protein fractions were prepared as previously described. For whole cell protein extraction, cells were lysed in 1 ml radioimmunoprecipitation assay lysis buffer. A total of 20 µg of protein was separated by 10% SDS-PAGE gel and subsequently transferred onto polyvinylidene fluoride membranes for western blot analysis. The following antibodies were used: Anti-hnRNP K (1:500); and HRP-conjugated secondary antibody (1:5,000).

**Statistical analysis.** Significant differences were determined by one-way analysis of variance and the independent samples t-test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Expression of hnRNP K in lung cancer tumors.** The rates of positive hnRNP K expression in lung tumors with diameters of ≤3, 3-5 and ≥5 cm, were 38.5, 95.2 and 91.7%, respectively (P<0.01; Fig. 1 and Table I).

**Expression of hnRNP K in A549 cells.** To examine the specific effect of hnRNP K siRNA treatment on hnRNP K expression in the A549 cell line, hnRNP K mRNA and protein expression levels were determined quantitatively using RT-PCR
and western blot analyses, respectively (Fig. 2 and Table II). hnRNP K mRNA and protein were markedly expressed in lung cancer A549 cells as reflected by RT‑PCR and western blot analysis. hnRNP K expression was decreased significantly at 24 h following transfection with specific hnRNP K siRNA.

**Effects of hnRNPK siRNA on cell cycle distributions and apoptosis rates.** Compared with the hnRNPK siRNA and untreated groups, specific hnRNP K siRNA caused an accumulation of cells in the G1 and S phases, decreased the number of cells in the G2/M phase and increased the hypodiploid DNA content (P<0.01) at 24 h following transfection (Table III). In the groups of specific hnRNP K siRNA, the apoptosis rate was 4.79% (Table III).

Discussion

The balance between the apoptosis and antiapoptosis signaling pathways is involved in the pathogenesis of a variety of cancers. It has been previously demonstrated that the inhibition of apoptosis promotes the mitotic progression in cancer cells (15). hnRNP K protein is an abundant factor involved in transcription, mRNA processing and other events that compose gene expression. It is likely that the increased K protein levels observed in the nuclei of the proliferating cells serve to support
nuclear processes that not only compose the inducible expression of a large number genes, but also maintains conducive chromatin topology in growing cells (16).

hnRNP K may promote cell proliferation and have a negative effect against the promotion of differentiation (17); in several states of enhanced cell proliferation, increased K protein levels have been identified in the nucleus. Induction of cell proliferation results in the activation of a large repertoire of genes (18). A previous study identified increased K protein expression in breast cancer cells. The authors provided evidence that the increased K protein levels contribute to the enhanced c-myc gene expression in such tumors (14).

In the present study, the expression and strength of hnRNP K was found to closely correlate with the size of tumor, specifically in the group of tumors with diameters of ≥3 cm, in which the positive rate of hnRNP K was >90%, a significant statistical difference compared with the group of tumors with diameters of ≤3 cm (the positive rate was 38.5%). This implied that hnRNP K may promote the growth and proliferation of lung cancer cells.

The c-Src interaction and activation domains in hnRNP K may be separated in vitro and in transfected cells. In the cellular context, the respective domains are present in hnRNP K. Therefore, the protein not only interacts with c-Src, as it does with lymphocyte-specific protein tyrosine kinase, but is also capable of activating c-Src in a specific manner. This supports the function of hnRNP K as a multifunctional scaffold protein that mediates the cross-talk between signaling pathways that controls cell differentiation and maturation (19).

By interfering with the expression of hnRNP K in A549 lung cancer cell strains, the present study identified that the expression of the hnRNP K protein and mRNA decreased evidently following interference with hnRNP K siRNA compared with the non-interference group. This indicated that the hnRNP K gene is inhibited in transcription and at the protein expression level. The results obtained from flow cytometry indicated that hnRNP K siRNA inhibits the growth of A549 lung cancer cell strains, in which the cells remain in the G0/G1 stage. In addition, the increase of subdiploid DNA implied that hnRNP K siRNA induces cell apoptosis.

A major consequence of p53 activation following DNA damage is the induction of cell-cycle arrest at the G1/S or G2/M transition stages. This is achieved primarily through the p53-induced expression of target genes that encode factors, such as p21WAF/CIP, a negative regulator of cyclin-dependent kinases (CDKs) that induces G1/S arrest (20) and proteins, such as GADD45, 14-3-3s and Reprim, which are required for an efficient G2/M arrest following DNA damage (21). The hnRNP K protein is required for p53-mediated transcription of cell cycle checkpoint genes (22). It enhances the transcription of oncogenes, such as c-myc and c-src and is considered to promote cell proliferation, survival and migration. hnRNP K has also been implicated in chromatin remodeling, mRNA splicing, export and translation (10). hnRNP K depletion abrogates the transcriptional induction of p53 target genes and causes defects in DNA damage-induced cell cycle checkpoint arrests. As a cofactor for p53, hnRNP K is key in coordinating transcriptional responses to DNA damage (22). hnRNP K is a multifunctional protein that has been studied primarily in cancer cells and has been suggested to be involved in cell cycle progression (23).

The results of the present study identified the significant increase of G0/G1 stage cells and significant decrease of G2/M stage cells in A549 lung cancer strains following transfection with hnRNP K siRNA. Previously, an inability of hnRNP K-depleted cells to induce p21, which normally mediates G1 arrest by inhibiting CDKs and by preventing the involvement of the proliferating cell nuclear antigen in DNA replication with DNA polymerase, has been identified (24,25). This result is consistent with the results of the current study, that the G0/G1 stage cells significantly increase in A549 strains following transfection with hnRNP K siRNA.

The present study supports that hnRNP K promotes the growth and proliferation of lung cancer cells and interfering with the hnRNP K expression may promote the apoptosis of lung cancer cells. Through the further investigation of the mechanism of hnRNP K promoting the growth and proliferation of lung cancer cells, new target sites of lung cancer therapy may be provided.

Acknowledgements

The authors would like to thank the patients and their families for participating in the study with patience and cooperation. The present study was supported by the National Natural Science Foundation of China (grant nos. 81241068 and 81201851) and the Sichuan Provincial Science and Technology Department programs, including the Science and Technology Support Program (grant no. 2011SZ0194), International Cooperation Program (grant no. 2011HH0051) and Application Foundation Program (grant no. 2013JY0012).

References

1. Krecic AM and Swanson MS: hnRNP complexes: composition, structure, and function. Curr Opin Cell Biol 11: 363-371, 1999.
2. Dreyfuss G, Matumis GM, Pirol-Roma S and Burd CG: hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem 62: 289-321, 1993.
3. Swanson MS: Functions of nuclear pre-mRNA/mRNA binding proteins. In: Pre-mRNA Processing. Lamond AL (ed). Springer-Verlag GmbH, Berlin, pp7-33, 1995.
4. Nigg EA: Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature 386: 779-787, 1997.
5. Nakielny S and Dreyfuss G: Nuclear export of proteins and RNAs. Curr Opin Cell Biol 9: 420-429, 1997.
6. Pirol-Roma S and Dreyfuss G: Transcription-dependent and transcription independent nuclear transport of hnRNP proteins. Science 253: 312-314, 1991.
7. Pirol-Roma S and Dreyfuss G: Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature 355: 730-732, 1992.
8. Carson JH, Kwon S and Barbarese E: RNA trafficking in myelinating cells. Curr Opin Neurobiol 8: 607-612, 1998.
9. Carpenter B, Mackay C, Alnabulsi A, et al: The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta 1765: 85-100, 2006.
10. Bomszyt K, Denisenko O and Ostrowski J: hnRNP K: one protein multiple processes. Bioessays 26: 629-638, 2004.
11. Bomszyt K, Van Seuningen I, Suzuki H, et al: Diverse molecular interactions of the hnRNP K protein. FEBS Lett 403: 113-115, 1997.
12. Micheletti EJ, Micheletti GA, Aronsohn AI and Levens D: Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol Cell Biol 16: 2350-2360, 1996.
13. Kühn H, Heydeck D, Brinkman R and Trebus F: Regulation of cellular 15-lipoxygenase activity on pretranslational, translational, and postranslational levels. Lipids 34 Suppl: S273-S279, 1999.
14. Mandle M, Vaudelami R, Nguyen D, et al: Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J Biol Chem 276: 9699-9704, 2001.
15. Kawamura K, Sato N, Fukuda J, et al: Survivin acts as an antiapoptotic factor during the development of mouse preimplantation embryos. Dev Biol 256: 331-341, 2003.
16. Ostrowski J and Bomsztyk K: Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br J Cancer 89: 1493-1501, 2003.
17. Yano M, Okano HJ and Okano H: Involvement of Hu and heterogeneous nuclear ribonucleoprotein K in neuronal differentiation through p21 mRNA post-transcriptional regulation. J Biol Chem 280: 12690-12699, 2005.
18. Iyer VR, Eisen MB, Ross DT, et al: The transcriptional program in the response of human fibroblasts to serum. Science 283: 83-87, 1999.
19. Adolph D, Flach N, Mueller K, et al: Deciphering the cross talk between hnRNP K and c-Src: the c-Src activation domain in hnRNP K is distinct from a second interaction site. Mol Cell Biol 27: 1758-1770, 2007.
20. Bartek J and Lukas J: Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 490: 117-122, 2001.
21. Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815, 2001.
22. Moumen A, Masterson P, O’Connor MJ and Jackson SP: hnRNP K: an HD-M2 target and transcriptional coactivator of p53 in response to DNA damage. Cell 123: 1065-1078, 2005.
23. Laury-Kleintop LD, Tresini M and Hammond O: Compartmentalization of hnRNP-K during cell cycle progression and its interaction with calponin in the cytoplasm. Cell Biochem 95: 1042-1056, 2005.
24. Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908, 2005.
25. Waga S, Hannon GJ, Beach D and Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.